Anixa Biosciences, Inc.
NASDAQ:ANIXBiotechnology
+$0.10 today
- Market cap
- $94.21M
- Beta
- 0.60
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$0.30
Volume 0.29M
Average 0.12M
ANIX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Anixa Biosciences, Inc.NASDAQ: ANIX
Selling, General & Admin · Q2 FY2026 · quarter ended Apr 2026
Selling, general & admin declines year over year
Q2 FY2026 selling, general & admin of $1.39M fell 17.4% year over year, behind the -10.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 13.9% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Oct 2026, a slowdown from the -10.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- $1.39M-13.9% QoQ
- Last fiscal yearOct 2025
- $6.63M-10.8% YoY
- LTMApr 2026
- $6.12M-10.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 6.63M USD
- Year-over-year change
- -10.8%
- 4-year CAGR
- -1.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 6.63M | -10.8% |
| FY2024 | 2024-10-31 | 7.44M | +18.2% |
| FY2023 | 2023-10-31 | 6.29M | -12.3% |
| FY2022 | 2022-10-31 | 7.17M | +1.4% |
| FY2021 | 2021-10-31 | 7.07M | — |
Selling, General & Admin vs competitors
How ANIX compares with its peers on the latest reported figures
- ANIX's LTM Apr 2026 selling, general & admin of $6.12M is the 8th highest of the 10 companies compared; the peer median is $19.24M.
- Its year-over-year change of -10.9% is the 6th highest of 10, against a peer median of -7.7%.
- Over three fiscal years its annual growth of -2.6% compares with a peer median of -6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.46B | +48531.9% | -28.7% | — | |
| LTM Mar 2026 | $45.53M | -35.6% | -12.4% | 36.8% | |
| LTM Mar 2026 | $40.57M | -24.5% | -6.8% | 269.8% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $21.57M | +8.6% | +44.6% | 180.0% |
| LTM Mar 2026 | $19.24M | -21.8% | -16.6% | 35.1% | |
| LTM Mar 2026 | $18.46M | -7.7% | +13.7% | — | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $12.2M | +39.9% | +47.3% | — |
| LTM Apr 2026 | $6.12M | -10.9% | -2.6% | — | |
| LTM Mar 2026 | $5.37M | +3.2% | -8.7% | — | |
| LTM Mar 2026 | $3.55M | -47.4% | +11.8% | — | |
| Peer median (excluding ANIX) | $19.24M | -7.7% | -6.8% | 108.4% | |
Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 512K | 0 | 210K | 0 | 0 |
| Cost of Revenue | 385K | 0 | 161K | 0 | 36K |
| Gross Profit | 127K | 0 | 49K | 0 | (36K) |
| Gross Margin | 24.8% | — | 23.3% | — | — |
| Research & Development | 6.19M | 6.7M | 4.77M | 6.4M | 5.07M |
| Selling, General & Admin | 7.07M | 7.17M | 6.29M | 7.44M | 6.63M |
| Operating Expenses | 13.26M | 13.88M | 11.06M | 13.83M | 11.67M |
| Depreciation & Amortization | 59.86K | 42K | 46K | 37K | 36K |
| EBITDA | (13.08M) | (13.73M) | (9.88M) | (12.66M) | (10.99M) |
| EBITDA Margin | -2554.9% | — | -4706.7% | — | — |
| Operating Income | (13.14M) | (13.88M) | (11.01M) | (13.83M) | (11.7M) |
| Operating Margin | -2565.6% | — | -5243.3% | — | — |
| Interest Income | 2.32K | 104K | 1.08M | 1.13M | 673K |
| Interest Expense | 322 | 104K | 0 | 0 | 0 |
| Other Income / Expenses | 7.77K | 104K | 1.08M | 1.13M | 673K |
| Income Before Tax | (13.13M) | (13.77M) | (9.93M) | (12.7M) | (11.03M) |
| Pre-Tax Margin | -2564.0% | — | -4728.6% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.95M) | (13.6M) | (9.81M) | (12.55M) | (10.93M) |
| Net Margin | -2528.6% | — | -4671.9% | — | — |
| EPS (Basic) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| EPS (Diluted) | (0.45) | (0.45) | (0.32) | (0.39) | (0.34) |
| Weighted Avg Shares | 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
| Weighted Avg Shares (Diluted) | 28.58M | 30.37M | 30.98M | 31.9M | 32.45M |
Anixa Biosciences, Inc.
NASDAQ:ANIX
Intrinsic Alpha fair value
Locked
Current Price
$2.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.